Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fenfluramine - Zogenix

Next Previous
Drug Profile

Fenfluramine - Zogenix

Alternative Names: Brabafen; Fenfluramine hydrochloride - Zogenix; FINTEPLA; Fintepla; FINTEPLA® CIV; Low-dose fenfluramine; ZX-008

Latest Information Update: 04 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Brabant Pharma
  • Developer Nippon Shinyaku; NYU Langone Medical Center; University Hospital Schleswig-Holstein; Zogenix
  • Class Amines; Amphetamines; Anorectics; Antiepileptic drugs; Fluorinated hydrocarbons; Small molecules
  • Mechanism of Action Serotonin receptor agonists; Serotonin release stimulants; Serotonin uptake inhibitors; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome; Dravet syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dravet syndrome; Lennox-Gastaut syndrome
  • Phase III Early infantile epileptic encephalopathy 2
  • Phase II Myoclonic epilepsies

Most Recent Events

  • 13 Nov 2023 Phase-III clinical trials in Dravet syndrome (In infants) in USA (PO) (NCT06118255)
  • 13 Nov 2023 Zogenix International terminates a phase III trial in Dravet Syndrome (In childrens, In adolescents) in USA (NCT03299842)
  • 07 Nov 2023 UCB BIOSCIENCES plans a phase III trial for Dravet Syndrome (In infants) in November 2023 (NCT06118255)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top